Dabigatran Etexilate Mesylate Patent Expiration
Dabigatran Etexilate Mesylate is used for preventing and treating blood clots. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Dabigatran Etexilate Mesylate Patents
Given below is the list of patents protecting Dabigatran Etexilate Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pradaxa | US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Feb 18, 2018
(Expired) | Boehringer Ingelheim |
| Pradaxa | US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Dec 28, 2021
(Expired) | Boehringer Ingelheim |
| Pradaxa |
US6087380 (Pediatric) | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun 28, 2022
(Expired) | Boehringer Ingelheim |
| Pradaxa | US7866474 | Film container | Aug 31, 2027 | Boehringer Ingelheim |
| Pradaxa |
US7866474 (Pediatric) | Film container | Mar 02, 2028 | Boehringer Ingelheim |
| Pradaxa | US7932273 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | Sep 07, 2025 | Boehringer Ingelheim |
| Pradaxa |
US7932273 (Pediatric) | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | Mar 07, 2026 | Boehringer Ingelheim |
| Pradaxa | US9034822 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | Jan 20, 2031 | Boehringer Ingelheim |
| Pradaxa |
US9034822 (Pediatric) | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | Jul 20, 2031 | Boehringer Ingelheim |
| Pradaxa | US9925174 | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun 14, 2023
(Expired) | Boehringer Ingelheim |
| Pradaxa |
US9925174 (Pediatric) | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec 14, 2023
(Expired) | Boehringer Ingelheim |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Dabigatran Etexilate Mesylate Generics
Several generic applications have been filed for Dabigatran Etexilate Mesylate. The first generic version for Dabigatran Etexilate Mesylate was by Alkem Laboratories Ltd and was approved on Mar 11, 2020. And the latest generic version is by Alembic Pharmaceuticals Ltd and was approved on Jun 14, 2024.
Given below is the list of companies who have filed for Dabigatran Etexilate Mesylate generic.
1. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 75MG BASE | capsule | Prescription | ORAL | AB | May 6, 2020 |
| EQ 150MG BASE | capsule | Prescription | ORAL | AB | May 6, 2020 |
2. MSN
Msn Laboratories Private Ltd has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 75MG BASE | capsule | Prescription | ORAL | AB | May 22, 2024 |
| EQ 150MG BASE | capsule | Prescription | ORAL | AB | May 22, 2024 |
3. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 75MG BASE | capsule | Prescription | ORAL | AB | Mar 11, 2020 |
| EQ 150MG BASE | capsule | Prescription | ORAL | AB | Mar 11, 2020 |
4. APOTEX
Apotex Inc has filed for 3 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 150MG BASE | capsule | Prescription | ORAL | AB | Dec 15, 2023 |
| EQ 110MG BASE | capsule | Prescription | ORAL | AB | Dec 15, 2023 |
| EQ 75MG BASE | capsule | Prescription | ORAL | AB | Dec 15, 2023 |
5. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Dabigatran Etexilate Mesylate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 75MG BASE | capsule | Prescription | ORAL | AB | Jun 14, 2024 |
| EQ 150MG BASE | capsule | Prescription | ORAL | AB | Jun 14, 2024 |